Completed PHASE3 INTERVENTIONAL 3-arm NCT01217515

Diltiazem Hydrochloride Cream for Anal Fissure

A Randomised,Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Diltiazem Hydrochloride Cream in Subjects With Anal Fissure

Sponsor: S.L.A. Pharma AG

Conditions Chronic Anal Fissure

Interventions Diltiazem hydrochloride 2% cream Diltiazem hydrochloride 4% cream Placebo

Updated 8 times since 2017 Last updated: Jul 7, 2014 Started: Oct 31, 2010 Primary completion: Mar 31, 2012 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Anal Fissure, this trial is completed. The trial is conducted by S.L.A. Pharma AG and has accumulated 8 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

S.L.A. Pharma AG

Data source: S.L.A. Pharma AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Blankenhain, Germany , Brighton, United Kingdom , Cluj Nopoca, Romania , Cluj-Napoca, Romania , Derby, United Kingdom , Deva, Romania , Fürth, Germany , Kaunas, Lithuania , Lasi, Romania , Mannheim, Germany and 12 more locations